A Bayesian decision‐theoretic approach to incorporate preclinical information into phase I oncology trials

Leveraging preclinical animal data for a phase I oncology trial is appealing yet challenging. In this paper, we use animal data to improve decision-making in a model-based dose-escalation procedure. We make a proposal for how to measure and address a prior-data conflict in a sequential study with a small sample size. Animal data are incorporated via a robust two-component mixture prior for the parameters of the human dose-toxicity relationship. The weights placed on each component of the prior are chosen empirically and updated dynamically as the trial progresses and more data accrue. After completion of each cohort, we use a Bayesian decision-theoretic approach to evaluate the predictive utility of the animal data for the observed human toxicity outcomes, reflecting the degree of agreement between dose-toxicity relationships in animals and humans. The proposed methodology is illustrated through several data examples and an extensive simulation study.

[1]  Aki Vehtari,et al.  A survey of Bayesian predictive methods for model assessment, selection and comparison , 2012 .

[2]  M. Kendall,et al.  Kendall's advanced theory of statistics , 1995 .

[3]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[4]  Siew Wan Hee,et al.  Designing a series of decision‐theoretic phase II trials in a small population , 2012, Statistics in medicine.

[5]  D. Spiegelhalter,et al.  Summarizing historical information on controls in clinical trials , 2010, Clinical trials.

[6]  Anthony O'Hagan,et al.  Bayesian heavy-tailed models and conflict resolution: A review , 2012 .

[7]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[8]  J Whitehead,et al.  Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. , 2001, Biostatistics.

[9]  Leonhard Held,et al.  Adaptive power priors with empirical Bayes for clinical trials , 2017, Pharmaceutical statistics.

[10]  R. Dresser.  First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless , 2009, Journal of Law, Medicine & Ethics.

[11]  Andrew Thomas,et al.  The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.

[12]  Martin Posch,et al.  Decision-theoretic designs for small trials and pilot studies: A review , 2015, Statistical methods in medical research.

[13]  R. A. Bailey,et al.  Statistical issues in first‐in‐man studies , 2007 .

[14]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[15]  Lisa V Hampson,et al.  A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials , 2020, Statistical methods in medical research.

[16]  G. Shapiro,et al.  First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[17]  Keying Ye,et al.  Using power priors to improve the binomial test of water quality , 2006 .

[18]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[19]  P. Müller,et al.  Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.

[20]  P. Thall,et al.  Practical Bayesian adaptive randomisation in clinical trials. , 2007, European journal of cancer.

[21]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.

[22]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[23]  N Stallard,et al.  Decision‐Theoretic Designs for Pre‐Phase II Screening Trials in Oncology , 2001, Biometrics.

[24]  J. McNeill,et al.  To scale or not to scale: the principles of dose extrapolation , 2009, British journal of pharmacology.

[25]  Heinz Schmidli,et al.  On the Use of Co-Data in Clinical Trials , 2016 .

[26]  Bradley P Carlin,et al.  Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation , 2017, Pharmaceutical statistics.

[27]  Fang Chen,et al.  Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.

[28]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[29]  J Whitehead,et al.  Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.

[30]  D. Draper,et al.  Stochastic Optimization: a Review , 2002 .

[31]  Stephen Duffull,et al.  Exposure response – getting the dose right , 2009, Pharmaceutical statistics.

[32]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[33]  John O'Quigley,et al.  Non-parametric optimal design in dose finding studies. , 2002, Biostatistics.

[34]  Phil Woodward,et al.  Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities , 2018, Therapeutic innovation & regulatory science.

[35]  N W Galwey,et al.  Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion? , 2017, Statistics in medicine.

[36]  Anthony O'Hagan,et al.  Kendall's Advanced Theory of Statistics, volume 2B: Bayesian Inference, second edition , 2004 .

[37]  Rosalind Walley,et al.  Addressing potential prior‐data conflict when using informative priors in proof‐of‐concept studies , 2016, Pharmaceutical statistics.

[38]  Lisa V Hampson,et al.  Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods , 2018, Statistical methods in medical research.

[39]  J Whitehead,et al.  Bayesian decision procedures for dose determining experiments. , 1995, Statistics in medicine.

[40]  Jorge Nocedal,et al.  A Limited Memory Algorithm for Bound Constrained Optimization , 1995, SIAM J. Sci. Comput..